January 06, 2025 02:23 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Bharatiya Janata Party releases first list of candidates for Delhi Assembly polls, fields Parvesh Sahib Singh Verma against Kejriwal | Firecracker unit explosion in Tamil Nadu's Virudhunagar kills 6 | Body of independent journalist, who went missing on Jan 1, found in a septic tank in Chhattisgarh | Delhi: 14-year-old student stabbed to death outside school after brawl with classmate | Rohit Sharma confirms he is not retiring amid speculations after skipping Sydney Test | India objects to China's 'new counties' announcement, says parts of these come under Ladakh | No cause for alarm over HMPV virus spread in China: Indian Health Agency | PM Modi gives a call for change in Delhi launching fierce attack on Arvind Kejriwal's AAP | Quran open to passage glorifying violence, bomb-making materials tracked in New Orleans attacker Shamshud-Din Jabbar's home | Jasprit Bumrah leads India in series decider after Rohit Sharma opts to rest in Sydney Test amid poor show with willow
AstraZeneca
Pixabay

AstraZeneca's COVID-19 vaccine trial to resume in US

| @indiablooms | Oct 24, 2020, at 03:28 pm

Washington/Xinhua: Multinational pharmaceutical company AstraZeneca said on Friday it will resume the trial of its experimental COVID-19 vaccine in the United States, which has been paused since September.

The company said the U.S. Food and Drug Administration (FDA) authorized the restart of the trial in the United States on Friday, following the resumption of trials in other countries in recent weeks.

The FDA reviewed all safety data from trials globally and concluded it was safe to resume the trial, said the company in a statement.

As part of the standard review process for trial safety events, a voluntary pause to vaccination across all global trials was triggered on Sept. 6 to allow the examination of safety data by independent monitoring committees, according to the company.

The recommendations from these reviews have been supported by international regulators, who also confirmed that the trials were safe to resume, said the statement.

AstraZeneca said results from the late-stage trials are expected later this year.  

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.